1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
In vivo dendritic cell reprogramming for cancer immunotherapy
2024) In Science (New York, N.Y.)(
- Contribution to journal › Article
- 2023
-
Mark
Restoring tumor immunogenicity with dendritic cell reprogramming
(
- Contribution to journal › Article
- 2022
-
Mark
Reprogramming primary melanoma cells to dendritic cell fate enhances tumor immunogenicity
2022) SITC Society for Immunotherapy of Cancer 2022(
- Contribution to conference › Poster
- 2021
-
Mark
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
(
- Contribution to journal › Article
- 2020
-
Mark
CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer
(
- Contribution to journal › Article
-
Mark
Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander CD8+ T cells in non-melanoma cancers compared to melanoma
(
- Contribution to journal › Article
- 2018
-
Mark
SATB1 in Malignant T Cells
(
- Contribution to journal › Article